DnB Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

DnB Asset Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.43M	Sell	17,986 -1,074	-6%	-$80.8K	﹤0.01%	620
2026 Q1	$1.43M	Buy	19,060 +4,222	+28%	+$333K	0.01%	611
2025 Q4	$1.17M	Buy	14,838 +5,530	+59%	+$416K	﹤0.01%	629
2025 Q3	$609K	Sell	9,308 -2,963	-24%	-$145K	﹤0.01%	661
2025 Q2	$485K	Buy	+12,271	New	+$402K	﹤0.01%	652
2021 Q2	–	Sell	-56,658	Closed	-$2.55M	–	641
2021 Q1	$2.55M	Buy	56,658 +32,277	+132%	+$1.8M	0.02%	489
2020 Q4	$1.38M	Buy	24,381 +9,459	+63%	+$471K	0.01%	528
2020 Q3	$708K	Hold	14,922	–	–	0.01%	561
2020 Q2	$880K	Buy	14,922 +1,696	+13%	+$94.3K	0.01%	525
2020 Q1	$625K	Sell	13,226 -2,663	-17%	-$148K	0.01%	548
2019 Q4	$960K	Buy	15,889 +1,600	+11%	+$95.3K	0.01%	584
2019 Q3	$856K	Buy	14,289 +721	+5%	+$47K	0.01%	564
2019 Q2	$872K	Buy	+13,568	New	+$959K	0.01%	558

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

DnB Asset Management's IONS Position: Q2 2026 in Review

DnB Asset Management reduced its Ionis Pharmaceuticals (IONS) stake by 5.6% in Q2 2026, selling an estimated $80.8K and leaving 17,986 shares worth $1.43M. The position accounts for ﹤0.01% of the portfolio, ranked #620.

DnB Asset Management first reported a position in IONS in Q2 2019 and has held it in 13 quarters since. The position peaked at $2.55M in Q1 2021. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

DnB Asset Management held 17,986 shares of Ionis Pharmaceuticals worth $1.43M as of Q2 2026.
DnB Asset Management sold 1,074 Ionis Pharmaceuticals shares in Q2 2026, an estimated $80.8K.
Ionis Pharmaceuticals made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #620 holding.
DnB Asset Management first reported a position in Ionis Pharmaceuticals in Q2 2019 and has held it in 13 quarters since.
DnB Asset Management's Ionis Pharmaceuticals position peaked at $2.55M in Q1 2021.
514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.